Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 143Neoplasm Metastasis 16Ovarian Neoplasms 6Advanced Breast Cancer 6Prostatic Neoplasms 5Breast Cancer Metastatic 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Lobular 3Lung Neoplasms 2HER2-positive Breast Cancer 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1The Neoadjuvant Therapy 1Stomach Neoplasms 1Solid Tumor 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Sarcoma 1Salivary Gland Neoplasms 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Malignant Neoplasms of Female Genital Organs 1

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HR Positive HER2 Negative Advanced Breast Cancer × Fulvestrant × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡